Vall D Hebron Institute Of Oncology
Vall D Hebron Institute Of Oncology is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
Sponsor Grupo Espanol Multidisciplinar En Cancer Digestivo
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC-2014-HNCG: PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study
Sponsor Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
- Start (EU)
- Latest update
- Estimated end
- Not reported
Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations
Sponsor Asociacion Grupo Tratamiento De Tumores Digestivos
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS
Sponsor Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Vall D Hebron Institute Of Oncology?
The 2026-10-09 snapshot links Vall D Hebron Institute Of Oncology to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Medical writing, Laboratory services, Project management, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Vall D Hebron Institute Of Oncology?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Haematological Malignancies, Hepatology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Vall D Hebron Institute Of Oncology conducted?
The linked trials record locations in 7 countries, including Spain, Germany, Italy, France, Belgium. These are trial locations, not confirmed office locations or countries where Vall D Hebron Institute Of Oncology delivered services.
What can this page tell me about Vall D Hebron Institute Of Oncology's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Vall D Hebron Institute Of Oncology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Vall D Hebron Institute Of Oncology